Phone: 81.72.366.0221; Email: haratani_k@med.kindai.ac.jp or koji_haratani@dfci.harvard.edu.
Category: biotech/medical
How dual-comb spectroscopy works and why it could reshape precision sensing
Spectroscopy has many applications, ranging from fundamental tests of quantum electrodynamics and investigations of molecular structure to environmental sensing, biomedical diagnostics and industrial monitoring. A highly promising spectroscopic instrument that has the potential to transform the field has emerged over the years: the dual-comb spectrometer, which relies on the interference of two mode-locked ultrafast lasers that produce broad frequency combs composed of evenly spaced narrow spectral lines.
A frequency comb is a spectrum of phase-coherent sharp laser lines that are evenly spaced. Such combs based on femtosecond mode-locked lasers, as pioneered at the Max-Planck Institute of Quantum Optics in the 1990s, have revolutionized measurements of frequency and time. In frequency metrology, a laser comb acts as a ruler in frequency space that conveniently links microwave and optical frequencies, and/or measures a large separation between two optical frequencies.
In the past two decades, frequency combs have found new applications. One of them is dual-comb spectroscopy. Dual-comb spectroscopy addresses the challenge of combining wide spectral coverage with high resolution and accuracy by using two optical frequency combs with slightly different repetition frequencies to map optical spectra directly into the radio-frequency domain. The method relies on time-domain interferometry and avoids mechanical scanning, enabling precise, rapid, and broadband measurements. Dual-comb spectroscopy has been implemented across the electromagnetic spectrum, from the terahertz to the visible range, with ongoing efforts towards the ultraviolet range.
The nocebo effect: How prior experience and verbal suggestion rewire the brain to make pain worse
Researchers have a better understanding of the nocebo effect and the neuroscience behind it all. Opposite of the better-known placebo effect, where positive expectations trigger genuine pain relief, the nocebo effect is the experience from negative expectations, created by prior experience, verbal suggestion, or social observation, which can drive anxiety and make pain worse.
A new study published in Nature Communications, by researchers at the University of Toronto Mississauga and McGill University, identified a brain pathway through which negative expectations can amplify pain. The findings, generated independently by the two labs without prior coordination, converged on the neurochemical cholecystokinin (CCK), which has previously been linked to nocebo pain responses in humans.
The researchers identified a specific brain pathway through which CCK acts, traveling from the brain’s anterior cingulate cortex (ACC), a region involved in the emotional dimensions of pain, to a midbrain structure called the lateral periaqueductal gray (lPAG), where it increases pain sensitivity.
Vitamin D analog shuts down pancreatic cancer’s shield in a clinical trial
A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.
In the study, published in Nature Cancer, patients with previously untreated metastatic pancreatic cancer received standard chemotherapy with or without paricalcitol, a vitamin D analog that is already FDA-approved for other uses. In patients who received paricalcitol orally or intravenously, the combination was found to be safe and to reduce activation of fibroblasts in the tumor microenvironment, validating Salk’s preclinical findings.
The trial was not intended to measure how well the approach works in treating pancreatic cancer, yet the researchers noted improved chemotherapy responses and increased progression-free survival at one year among patients who received paricalcitol plus chemotherapy. In addition, they found that patients with high vitamin D receptor expression and who received paricalcitol had the longest overall survival.
Progress in stem cell therapy for type 1 diabetes
Researchers at Karolinska Institutet and KTH Royal Institute of Technology have developed an improved method for creating insulin-producing cells from human stem cells. The results, published in Stem Cell Reports, demonstrate that these cells effectively regulate blood sugar levels in laboratory tests and can reverse diabetes in mice.
DeepMind’s Insane AI Breakthroughs With CEO Demis Hassabis
Thank you to Google DeepMind for the invite. 🙏
❤️ Check out Lambda here and sign up for their GPU Cloud: https://lambda.ai/papers.
Our Patreon if you wish to support us: / twominutepapers.
🙏 We would like to thank our generous Patreon supporters who make Two Minute Papers possible:
Adam Bridges, Benji Rabhan, B Shang, Cameron Navor, Charles Ian Norman Venn, Christian Ahlin, Eric T, Fred R, Gordon Child, Juan Benet, Michael Tedder, Owen Skarpness, Richard Sundvall, Ryan Stankye, Shawn Becker, Steef, Taras Bobrovytsky, Tazaur Sagenclaw, Tybie Fitzhugh, Ueli Gallizzi.
My research: https://cg.tuwien.ac.at/~zsolnai/
Thumbnail design: https://felicia.hu.
00:00 Intro.
Structural biologists are first in world to visualize key cell protein
University of Cincinnati structural biologists are the first in the world to visualize a key cell protein as part of newly published research from the College of Medicine. The Seegar Lab has become the first to visualize the structure of a regulator protein, iRhom1, bound to the ADAM17 enzyme, using cryogenic electron microscopy housed in UC’s Center for Advanced Structural Biology research facility.
This follows the lab’s work published last year that visualized the structure of ADAM17 bound to iRhom2.
ADAM17 enzyme activity is essential in humans for proper tissue development and immune response, and regulating its activity is a drug target in treating chronic inflammatory diseases. Ectodomain shedding is the fundamental biological process in which enzymes, such as ADAM17, rapidly cleave and release other protein targets from the cell surface, altering cell-to-cell communication.
My Video Tour of Alcor and Interview with CEO Max More
What counts as death? And who gets to decide?
In the summer of 2013, I traveled to Scottsdale, Arizona to visit the Alcor Life Extension Foundation, the world’s leading cryonics organization, founded in 1972. CEO Dr. Max More gave me a full tour of the facilities and walked me through the entire process: from the moment clinical death is declared, through controlled cooling and vitrification, to the cryo-tanks holding (at the time) 117 patients in long-term storage.
I also asked him, somewhat selfishly, whether my big bald head would fit comfortably in a neuro-patient container.
After the tour, Max sat down with me for a 25-minute conversation that covered:
Affordability and the real cost of membership Why minimizing cooling delays after clinical death is critical, and what long-distance members do about it Preserving pets, because of course people ask Chemical brain preservation as an alternative path The importance of protecting the neuron’s microtubules The case for an X Prize style competition to reduce tissue damage Where cryonics sits inside the broader transhumanist project.
My favorite line from Max, the one I still come back to: